CYFUSE BIOMEDICAL K K: Confirmation letter
CYFUSE BIOMEDICAL K K: Quarterly Report - First quarter of the 15th term (2024/01/01 to 2024/03/31)
CYFUSE BIOMEDICAL K K: Notice regarding completion of payment of the issuance of new shares as a stock reward with transfer restrictions
CYFUSE BIOMEDICAL K K: Summary of financial results for the 1st quarter of the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)
CYFUSE BIOMEDICAL K K: Notice regarding adoption and participation in the AMED public offering project “Bridging Research Program”
CYFUSE BIOMEDICAL K K: Notice Concerning Issuance of New Shares as Stock Compensation with Transfer Restricted Shares
CYFUSE BIOMEDICAL K K: Extraordinary Report
Cyfuse: Corporate Governance Report 2024/03/27
Scifuse: Extraordinary Report
Cyfuse Biomedical KK: Internal Control Report - Term 14 (2023/01/01 - 2023/12/31)
Syfuse: Confirmation Letter
Scifuse: Financial Report - Term 14 (2023/01/01 - 2023/12/31)
Cyfuse Biomedical KK: Matters relating to business plans and growth potential
Cyfuse Biomedical KK: Change Report
Cyfuse: Notice regarding the recording of non-operating income
Scifuse: Notice of Convocation of the 2023/12 Annual General Meeting of Shareholders and General Shareholders' Meeting Materials
Cyfuse: World's First 3D Neural Conduit Transplantation for Peripheral Nerve Injury - Doctor-Led Clinical Trial Results and Toward Social Implementation
Scifuse: Financial results presentation materials for the fiscal year ending 2023/12
Scifuse: change report
Cyfuse Biomedical KK: Summary of financial results for the fiscal year ending 2023/12 [Japanese GAAP] (unconsolidated)
No Data